Last updated:
Psilocybe Mexicana
"Mexican Psilocybe, Mexicana"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeMexicana-1_new-800x450.webp)
Scientific Classification
About
Psilocybe mexicana is a small but culturally and historically significant psychedelic mushroom, native to Mexico and Central America. Known for its mild potency and deeply introspective effects, this species is revered as one of the original sacred mushrooms used in indigenous Mesoamerican rituals for thousands of years. It is also notable as the species from which psilocybin and psilocin were first isolated by Dr. Albert Hofmann in 1958.
History
The use of Psilocybe mexicana dates back to the Aztecs, who called it "teonanácatl", meaning “flesh of the gods.” It was central to religious ceremonies designed to connect with divine forces, guided by shamans or priests. During the Spanish conquest, its use was suppressed but survived in secret among indigenous communities in Oaxaca.
In the 1950s, it became the focus of Western psychedelic interest after R. Gordon Wasson’s expeditions with Mazatec curandera María Sabina. Hofmann later synthesized psilocybin from this species, launching decades of medical research into its psychoactive properties.
Overview
A small mushroom, typically 1–3 cm in cap diameter, with a conic to bell-shaped, yellow-brown cap and slender stem. It bruises blue when handled, indicating the presence of psilocybin. Its gills are adnate to adnexed and turn dark purple as spores mature.
Psilocybe mexicana has moderate potency and produces effects such as altered perception, emotional insight, and visual phenomena. It is consumed fresh, dried, or as sclerotia, which are denser fungal growths also containing psilocybin. While often used in ceremonial settings, it is increasingly recognized in modern therapeutic contexts.
Physical Characteristics
Caps:
Conic to campanulate, hygrophanous, 1-3 cm wide, reddish-brown to yellowish-brown when moist, fading to pale ochre when dry
Gills:
Adnate to adnexed, initially pale, becoming purplish-black with age
Psychoactive Effects
Euphoric
Describing intense feelings of happiness or excitement
Perceptual
The change in the way things are perceived, including changes in time perception, spatial perception, and perception of one's own body.
Pharmacology
Helps With
Depression
Relieves symptoms of depression, improving mood and outlook
Anxiety
Helps to alleviate feelings of worry, fear, and unease
Addiction
Helps to overcome addiction and substance abuse
PTSD
Helps to alleviate symptoms of post-traumatic stress disorder
OCD
Helps to alleviate symptoms of obsessive-compulsive disorder
ADD ADHD
Helps to alleviate symptoms of attention deficit disorder and attention deficit hyperactivity disorder
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines. A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
A feeling of discomfort in the stomach with an urge to vomit
Grow at Home
Start your cultivation journey with quality grow kits from verified vendors
Chemical Constituents
Medicinal Chemistry
Similar Species
Key Differences: P. subtropicalis typically has a larger cap and a thicker stem compared to P. mexicana.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeSubtropicalis_new-400x400.webp)
Species: Psilocybe Subtropicalis
(Subtropical Psilocybe)
Edibility: Psychoactive
Mushroom Ratings
4.3
(3)
Based on 3 Reviews
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
01/29/2025
Victor Romo
01/29/2025
Ruth Zota
01/29/2025
Ruth Zota
References
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .
- Schindler, E. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. .
- Raval, N. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. .
- Kuypers, K. (2019). Psychedelic medicine: The biology underlying the persisting psychedelic effects. .